JNJ-7706621
| Title | Journal |
|---|---|
| Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. | ACS medicinal chemistry letters 20170608 |
| ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. | Proceedings of the National Academy of Sciences of the United States of America 20150414 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | The Biochemical journal 20130415 |
| Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. | Current cancer drug targets 20120701 |
| Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase. | The Biochemical journal 20111115 |
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | Nature biotechnology 20111101 |
| Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. | European journal of medicinal chemistry 20110601 |
| Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3. | Bioorganic & medicinal chemistry letters 20101215 |
| Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. | International journal of pharmaceutics 20100615 |
| A quantitative analysis of kinase inhibitor selectivity. | Nature biotechnology 20080101 |
| Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. | Molecular cancer therapeutics 20061001 |
| 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. | Journal of medicinal chemistry 20050630 |